Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05806268 · ClinicalTrials.gov registry record
Patient Characteristics, Associated Factors, and Clinical Outcomes of Prescribing Encorafenib and Binimetenib Versus Dabrafenib and Trametinib Among BRAF v600 Mutated Metastatic Melanoma Patients
A clinical trial, sponsored by Novartis Pharmaceuticals.
- Completed
- Registry status
- 214
- Enrollment target
NCT05806268 is a clinical trial that has completed, run by Novartis Pharmaceuticals. The registered enrollment target is 214 participants.
The verdict
NCT05806268 has completed, sponsored by Novartis Pharmaceuticals.
- COMPLETED
- Registry status
- 214 participants
- Enrollment target
Study Summary
This was a retrospective real-world evidence cohort study. The study was conducted using the NOBLE (Novartis Braf+ meLanoma patients ObsErvational) dataset, with a study period from 01 January 2011 to 31 May 2020. All included patients were ≥18 years of age and were required to have a diagnosis of unresectable stage III or IV melanoma (ICD-9 172.x \& ICD-10 C43 or D03x), treatment with dabrafenib and trametinib (dab/tram) or encorafenib and binimetenib (enco/bini) on or after 01 June 2018, and evidence of a BRAF-positive result prior to or up to 30 days after therapy initiation. No quota of centers was established a priori. Given the retrospective nature of this study, all patients who met the inclusion/exclusion criteria from the NOBLE dataset were included.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 214 participants |
| Start Date | 2021-07-30 |
| Est. Completion | 2022-03-28 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05806268
The ClinicalTrials.gov registry entry for NCT05806268 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 214 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Novartis Pharmaceuticals, which has 1,375 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 0 interventions.
NCT05806268 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05806268 about?
NCT05806268 is a clinical study titled "Patient Characteristics, Associated Factors, and Clinical Outcomes of Prescribing Encorafenib and Binimetenib Versus Dabrafenib and Trametinib Among BRAF v600 Mutated Metastatic Melanoma Patients". This was a retrospective real-world evidence cohort study. The study was conducted using the NOBLE (Novartis Braf+ meLanoma patients ObsErvational) dataset, with a study period from 01 January 2011 to 31 May 2020. All included patients were ≥18 years of age and were required to have a diagnosis of u...
What is the current status of trial NCT05806268?
This trial is currently completed. The enrollment target is 214 participants. The study started on 2021-07-30. Estimated completion is 2022-03-28.
Who is sponsoring clinical trial NCT05806268?
This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.